Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148378 | 0.94 | NR1H4 (0.48) | MAP4K4PDE4BPTGER1PARP15PARP10 | |
| SCHEMBL12420684 | 0.84 | XDH (0.53) | MAP4K4PDE4BPTGER1XDHPARP15 | |
| SCHEMBL6940040 | 0.84 | TSHR (0.62) | MAP4K4PDE4BXDHPDE4APDE4C | |
| SCHEMBL10148081 | 0.83 | MAP4K4 (0.54) | MAP4K4PDE4BPTGER1XDHPARP15 | |
| SCHEMBL663986 | 0.83 | MAP4K4 (0.54) | MAP4K4PTGER1XDHPARP15PARP10 | |
| SCHEMBL30863550 | 0.83 | RBP4 (0.47) | PDE4BMRGPRX4 | |
| SCHEMBL27195879 | 0.83 | RBP4 (0.47) | PDE4BMRGPRX4 | |
| SCHEMBL17050363 | 0.82 | NR1H4 (0.48) | MAP4K4PDE4BXDHPARP15PARP10 | |
| SCHEMBL7389578 | 0.82 | PDE4B (0.60) | PDE4BPARP15PARP10PDE4APDE4C | |
| SCHEMBL17908114 | 0.81 | PTGER1 (0.56) | PTGER1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | MAP4K4 3718/4885PDE4B 1283/4885PTGER1 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.